ABU DHABI-BASED LAB HARNESSES GENERATIVE AI FOR BREAKTHROUGHS IN DRUG DISCOVERY AND HEALTHCARE

An Abu Dhabi-based company, Insilico Medicine, is utilizing Generative AI to develop new drug solutions for cancer, COVID-19, and rare diseases. The company has opened the largest AIpowered biotech R&D center in the UAE’s capital, which has validated its generative AI technology platform called Pharma. Insilico Medicine has incorporated robotics and AlphaFold2 deep learning system into their platform. Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, in his statement to Al Arabia English highlighted the opportunities for the Middle East in the generative AI industry and its potential in various sectors, including sustainable fuels. He emphasized the region’s scientific and technological expertise and partnership opportunities for growth in the biotech industry.

Insilico Medicine’s establishment of the Generative Artificial Intelligence and Quantum Computing Research and Development Center in Abu Dhabi demonstrates the region’s commitment to advancing AI-driven solutions in the healthcare and pharmaceutical sectors. With the rising demand for innovative therapies and treatments, the company’s focus on using Generative AI for drug discovery holds great promise. By leveraging cutting-edge technologies and partnering with government and academic institutions, Insilico Medicine is paving the way for the Middle East to become a prominent player in the biotech industry and contribute to advancements in healthcare on a global scale. n